title: Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
abstract: LY-450139 is a gamma-secretase inhibitor shown to have efficacy in multiple cellular and animal models. Paradoxically, robust elevations of plasma amyloid-beta (Abeta) have been reported in dogs and humans after administration of subefficacious doses. The present study sought to further evaluate Abeta responses to LY-450139 in the guinea pig, a nontransgenic model that has an Abeta sequence identical to that of human. Male guinea pigs were treated with LY-450139 (0.2-60 mg/kg), and brain, cerebrospinal fluid, and plasma Abeta levels were characterized at 1, 3, 6, 9, and 14 h postdose. Low doses significantly elevated plasma Abeta levels at early time points, with return to baseline within hours. Higher doses inhibited Abeta levels in all compartments at early time points, but elevated plasma Abeta levels at later time points. To determine whether this phenomenon occurs under steady-state drug exposure, guinea pigs were implanted with subcutaneous minipumps delivering LY-450139 (0.3-30 mg/kg/day) for 5 days. Plasma Abeta was significantly inhibited at 10-30 mg/kg/day, but significantly elevated at 1 mg/kg/day. To further understand the mechanism of Abeta elevation by LY-450139, H4 cells overexpressing the Swedish mutant of amyloid-precursor protein and a mouse embryonic stem cell-derived neuronal cell line were studied. In both cellular models, elevated levels of secreted Abeta were observed at subefficacious concentrations, whereas dose-responsive inhibition was observed at higher concentrations. These results suggest that LY-450139 modulates the gamma-secretase complex, eliciting Abeta lowering at high concentrations but Abeta elevation at low concentrations.
authors.affiliation: Pfizer, Inc., Eastern Point Rd., MS# 8220-4183, Groton, CT 06340, USA. thomas.a.lanz@pfizer.com
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Lanz
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Karmilowicz
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Wood
authors.forename: Nikolay
authors.initials: N
authors.lastname: Pozdnyakov
authors.forename: Ping
authors.initials: P
authors.lastname: Du
authors.forename: Mary A
authors.initials: MA
authors.lastname: Piotrowski
authors.forename: Tracy M
authors.initials: TM
authors.lastname: Brown
authors.forename: Charles E
authors.initials: CE
authors.lastname: Nolan
authors.forename: Karl E G
authors.initials: KE
authors.lastname: Richter
authors.forename: James E
authors.initials: JE
authors.lastname: Finley
authors.forename: Qing
authors.initials: Q
authors.lastname: Fei
authors.forename: Charles F
authors.initials: CF
authors.lastname: Ebbinghaus
authors.forename: Yuhpyng L
authors.initials: YL
authors.lastname: Chen
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Spracklin
authors.forename: Barbara
authors.initials: B
authors.lastname: Tate
authors.forename: Kieran F
authors.initials: KF
authors.lastname: Geoghegan
authors.forename: Lit-Fui
authors.initials: LF
authors.lastname: Lau
authors.forename: David D
authors.initials: DD
authors.lastname: Auperin
authors.forename: Joel B
authors.initials: JB
authors.lastname: Schachter
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D016229:Amyloid beta-Peptides / Q000097:blood*; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D013997:Time Factors
chemical_list: D016229:Amyloid beta-Peptides; D001381:Azepines; D004791:Enzyme Inhibitors; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine